Fidelity Digital Health ETF(FDHT.US)

Intuitive Surgical Reports 21% Revenue Growth for 2025

Intuitive Surgical Inc. reported a 21% revenue growth for 2025, with preliminary full-year revenue reaching approximately $10.06 billion. The fourth quarter revenue was about $2.87 billion, a 19% increase from the previous year. Worldwide procedures using the da Vinci and Ion platforms grew by 18%, with da Vinci procedures up 17% and Ion procedures up 44%. The company placed 1,721 da Vinci systems in 2025, including 870 da Vinci 5 systems. A conference call to discuss full financial results is scheduled for January 22, 2026.

Veeva Systems unveils industry cloud strategy and AI innovations for life sciences in new presentation

Veeva Systems Inc. presented its industry cloud strategy and AI innovations for life sciences at the J.P. Morgan 2026 Healthcare Conference. The company emphasized its cloud solutions for development, quality, commercial, and data management needs. Veeva highlighted its structural advantages and discussed industry changes, including the rise of artificial intelligence and a more connected ecosystem.

Insulet Corporation highlights diabetes management leadership and market growth in new investor presentation

Insulet Corporation showcased its leadership in diabetes management at the J.P. Morgan 44th Annual Healthcare Conference. The company highlighted its FDA-cleared Automated Insulin Delivery (AID) system, which is the most prescribed in the U.S. Insulet anticipates approximately $2.7 billion in revenue for 2025 and has over 600,000 active customers globally. The company has contributed to two-thirds of the AID market growth from 2020 to 2025, achieving a 26% CAGR and nearing a 50% share of global revenue in this segment.

Glucose monitor maker Dexcom's prelim Q4 revenue beats expectations on G7 15 Day launch

Dexcom, a glucose monitoring company, reported preliminary Q4 revenue growth of 13%, surpassing analyst expectations. The growth is attributed to the launch of its G7 15 Day sensor technology. For fiscal 2025, revenue is projected to increase by 16% year-over-year, with an anticipated revenue of $5.16 - $5.25 billion for 2026, reflecting an 11-13% growth. The company also noted a strong international revenue increase of 18% in Q4. Analysts maintain a "buy" rating on Dexcom shares, with a median 12-month price target of $84.71, indicating a potential upside from its current trading price.

DexCom | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 1.26 B